Therefore, the findings of this review will facilitate in exploring the controlling role of NOTCH1 amongst other genes in PTCL progression and development in order to be used in enhancing the overall survival rate and treatment plans, such as immunotherapy (CAR-T), ADCs and BiTE antibodies targeting against the NOTCH1 gene. This evidence concerns the gene NOTCH1 and mature T-cell and NK-cell non-Hodgkin lymphoma.